Rigel Pharmaceuticals (RIGL) Common Equity (2010 - 2026)

Rigel Pharmaceuticals has reported Common Equity for 17 years, with the latest figure at $399.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 2053.81% year-over-year to $399.9 million; the trailing twelve-month figure through Mar 2026 stood at $399.9 million (up 2053.81% YoY), and the FY2025 full-year result was $391.5 million, up 11806.33% from the prior year.
• Common Equity for Q1 2026 stood at $399.9 million, up from $391.5 million in the prior quarter.
• The five-year high for Common Equity was $399.9 million in Q1 2026, with the low at -$31.8 million in Q3 2023.
• Average Common Equity over 5 years is $46.7 million, with a median of -$13.6 million recorded in 2022.
• Year-over-year, Common Equity sank 664.62% in 2023 and jumped 11806.33% in 2025.
• Tracing RIGL's Common Equity over 5 years: stood at -$13.6 million in 2022, then slumped by 110.37% to -$28.6 million in 2023, then soared by 111.48% to $3.3 million in 2024, then jumped by 11806.33% to $391.5 million in 2025, then advanced by 2.15% to $399.9 million in 2026.
• The last three Common Equity figures came in at $399.9 million (Q1 2026), $391.5 million (Q4 2025), and $117.6 million (Q3 2025), per Business Quant data.

Peer Comparison